Yoichi Hamai
Overview
Explore the profile of Yoichi Hamai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
665
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saita K, Tanabe K, Hamai Y, Yamauchi M, Kaneko F, Mikami Y, et al.
J Cancer Surviv
. 2025 Feb;
PMID: 39954221
Purpose: Risk factors for cancer-related cognitive impairment (CRCI) are diverse; neuroimaging instruments are recommended to complement subjective and objective cognitive assessments. This study aimed to evaluate the feasibility of a...
2.
Ohsawa M, Nishi H, Emi M, Yoshikawa T, Hamai Y, Ibuki Y, et al.
J Radiat Res
. 2024 Dec;
65(Supplement_1):i126-i134.
PMID: 39679879
Despite advances in multimodality therapy, including surgery, chemotherapy, radiation therapy and chemoradiation, the fatality rate for esophageal cancer remains high. Specifically, Fusobacterium nucleatum, due to its aggregation capacity, has shown...
3.
Hirohata R, Yamamoto Y, Mimae T, Hamai Y, Ibuki Y, Takahashi R, et al.
Ann Surg Oncol
. 2024 Nov;
32(2):789-790.
PMID: 39546104
No abstract available.
4.
Hamai Y, Ibuki Y, Kurokawa T, Hirohata R, Ohsawa M, Kitasaki N, et al.
Cancers (Basel)
. 2024 Oct;
16(20).
PMID: 39456623
Background: Patients across various cancers who develop immune-related adverse events (irAEs) post-immune checkpoint inhibitor (ICI) treatment tend to experience better tumor response and survival than those who do not. However,...
5.
Hirohata R, Yamamoto Y, Mimae T, Hamai Y, Ibuki Y, Takahashi R, et al.
Ann Surg Oncol
. 2024 Oct;
32(1):570-580.
PMID: 39419890
Background: The authors hypothesized that small ribonucleic acid (sRNA) obtained from blood samples after neoadjuvant therapy from patients treated with neoadjuvant chemoradiation therapy (NACRT) could serve as a novel biomarker...
6.
Ohsawa M, Hamai Y, Emi M, Ibuki Y, Kurokawa T, Hirohata R, et al.
Surgery
. 2024 Oct;
178():108863.
PMID: 39419644
Background: Patients diagnosed with pathologic T1N0 esophageal squamous cell carcinoma and treated with surgery alone have a good prognosis and are generally followed up without adjuvant therapy. However, recurrence has...
7.
Tsuji T, Matsuda S, Sato Y, Tanaka K, Sasaki K, Watanabe M, et al.
Ann Surg Oncol
. 2024 Oct;
32(1):325-326.
PMID: 39354244
No abstract available.
8.
Tsuji T, Matsuda S, Sato Y, Tanaka K, Sasaki K, Watanabe M, et al.
Ann Surg Oncol
. 2024 Sep;
32(1):274-283.
PMID: 39266786
Background: Patients with esophageal squamous cell carcinoma (ESCC) with distant metastasis were treated with systemic chemotherapy. Recent advances in multimodal treatments have made conversion therapy a viable option for patients...
9.
Booka E, Takeuchi H, Kikuchi H, Miura A, Kanda M, Kawaguchi Y, et al.
Esophagus
. 2024 Sep;
22(1):19-26.
PMID: 39242403
Background: Cricothyrotomy is a widely performed potentially life-saving treatment to secure an airway in emergencies. It is also a pneumonia-preventing treatment to secure an expectorant route in patients with difficulty...
10.
Hirohata R, Hamai Y, Emi M, Ibuki Y, Kurokawa T, Ohsawa M, et al.
World J Surg
. 2024 May;
48(7):1700-1709.
PMID: 38757868
Background: Prognosis of patients who achieve pathological complete response (pCR) with neoadjuvant therapy (NAT) is better than that of non-pCR patients. Currently, there is no indication for adjuvant immune checkpoint...